OraSure to Launch OraQuick™ HIV Self-Test in Canada

BETHLEHEM, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its OraQuick™ HIV Self-Test has received a license from Health Canada for use in Canada.

GlobeNewsWire • Feb 10, 2026

OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th

BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026.

GlobeNewsWire • Feb 9, 2026

OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital

BETHLEHEM, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has nominated two candidates, including the fund's founder Rishi Bajaj, to stand for election to the Company's Board of Directors (the “Board”) at its 2026 Annual Meeting of Stockholders.

GlobeNewsWire • Jan 15, 2026

Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors

LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has nominated two highly-qualified candidates, John Bertrand, Co-Founder of Digital Diagnostics, and Rishi Bajaj, President and CIO of Altai, for election to the OraSure Board of Directors (the “Board”) at the 2026 Annua.

Business Wire • Jan 15, 2026

OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device

OSUR files FDA applications seeking approval for two at-home STI tests, advancing decentralized diagnostics; shares gain 3.8% as it targets long-term growth.

Zacks Investment Research • Jan 6, 2026

OraSure Technologies Issues Statement Regarding Altai Capital's Intent to Nominate Director Candidates

BETHLEHEM, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has notified the Company of its intent to nominate two candidates, including the fund's founder, Rishi Bajaj, to stand for election to the Company's Board of Directors (the “Board”) at its 2026 Annual Meeting of Stockholders.

GlobeNewsWire • Dec 17, 2025

Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors

LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. (“Altai”), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter notifying the OraSure Board of Directors (the “Board”) of Altai's intention to nominate two highly-qualified candidates, John Bertrand, CEO of Digital Diagnostics, and Rishi Bajaj, President and CI.

Business Wire • Dec 17, 2025

OraSure Technologies, Inc. (OSUR) Q3 2025 Earnings Call Transcript

OraSure Technologies, Inc. ( OSUR ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Jason Plagman - Vice President of Investor Relations Carrie Eglinton Manner - President, CEO & Director Kenneth McGrath - Chief Financial Officer Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the OraSure Technologies, Inc. 2025 Third Quarter Earnings Conference Call.

Seeking Alpha • Nov 6, 2025

OraSure Technologies (OSUR) Reports Q3 Loss, Lags Revenue Estimates

OraSure Technologies (OSUR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.01 per share a year ago.

Zacks Investment Research • Nov 6, 2025

OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th

BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain business developments for 5 p.m. ET on November 5, 2025.

GlobeNewsWire • Oct 29, 2025